Metacrine (MTCR) Stock Analysis
NASDAQHealthcareBiotechnology
What Metacrine does
Metacrine, Inc., established in 2014 and operating from its headquarters in San Diego, California, is a clinical-stage biopharmaceutical company. The firm's core mission involves identifying and advancing novel therapies specifically designed for patients suffering from gastrointestinal disorders. Among its developmental pipeline, Metacrine is progressing MET642, a therapeutic candidate which has successfully completed its Phase I clinical investigation aimed at treating ulcerative colitis.
Key metrics
ETFs linked to MTCR
Broad-market and Healthcare sector ETFs an investor holding Metacrine is often also exposed to. Open an ETF page to see its actual top holdings.
PortView Portfolio Insights
PortView analyzes how MTCR fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.
Analyze MTCR in PortView →Similar companies
Frequently asked questions
- What is the ticker symbol for Metacrine?
- Metacrine trades under the ticker MTCR on NASDAQ.
- Which exchange is MTCR listed on?
- MTCR is listed on NASDAQ.
- What sector does Metacrine operate in?
- Metacrine is classified in the Healthcare sector (Biotechnology industry).
- How can PortView help analyze MTCR in a portfolio?
- PortView shows MTCR's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.
The information provided by PortView is for informational and educational purposes only and does not constitute investment advice. Market data may be delayed. Past performance does not guarantee future results.